Skip to main content
SpringerLink
Log in

Quality-of-Life Assessment in Comparative Therapeutic Trials and Causal Structure Considerations in Peripheral Occlusive Arterial Disease

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

When considering the use of quality of life as a primary end-point in phase III to IV comparative trials, the trial designer generally faces some unresolved questions. These include:

  • How does one explain that some dimensions [quality-of-life (QOL) instruments usually have more than 1 dimension] are directly influenced by the studied treatments whereas others are not?

  • How can one interpret conflicting results between conventional clinical measurements and QOL measurements, when the relationships between conventional clinical measurement and quality of life are not known?

In this paper, we consider the use of Structural Equation Modelling (SEM) as a methodological alternative to answer these problems. As an example, we analyse the internal causal structure of the Claudication Scale (CLAU-S), a specific QOL 5-dimensional instrument for peripheral occlusive arterial disease. In applying SEM to different studies and different types of calculation, we suggest that CLAU-S is based on a stable, simple and comprehensive QOL model, is compatible with the general International Classification of Impairments, Disabilities and Handicaps (ICIDH) classification, is coherent and complementary with clinical data measurements and, using differences in a prospective study, considerably improves specificity.

We suggest that SEM can help in QOL scale validation, in providing a unified scheme of the inter-relationships between internal dimensions and with external variables, in particular, clinical measurements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit. Note for guidance on the chronic peripheral arterial occlusive disease. CPMP Efficacy Working Party — November 1995

    Google Scholar 

  2. Guyatt GH, Veldhuizen Van Zanten SJO, Feeny DH, et al. Measuring quality of life in clinical trials: a taxonomy and review. Can Med Assoc J 1989; 140: 1441–8

    CAS  Google Scholar 

  3. Hollenberg NK, Testa M, Williams GH. Quality of life as a therapeutic end-point: an analysis of therapeutic trials in hypertension. Drug Saf 1991; 6(2): 83–93

    Article  PubMed  CAS  Google Scholar 

  4. Chow SC, Ki FY. On statistical characteristics of quality of life assessment. J Biopharm Stat 1994; 4(1): 1–17

    Article  PubMed  CAS  Google Scholar 

  5. Creutzig A, Bullinger M, Cachovan M, et al. Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication. Vasa 1997; 26: 122–7

    PubMed  CAS  Google Scholar 

  6. Regensteiner JG, Steiner JF, Panzer RJ, et al. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990; 2: 142–52

    Google Scholar 

  7. Finger T, Kirchberger I, Dietze S, et al. Assessing the quality of life of patients with intermittent claudication; psychometric properties of the claudication scale (CLAU-S). Qual Life Res 1995; 4: 122–7

    Google Scholar 

  8. Otis RB, Brown AS, Womack CJ, et al. Relationship between physical activity recall and free-living daily physical activity in older claudicants. Angiology 2000; 51(3): 181–8

    Article  PubMed  CAS  Google Scholar 

  9. Bullinger M, Cachovan M, Creutzig A, et al. Entwicklung eines krankheirsspezifischen instruments zur erfassung der lebensqualität von patienten mit arterieller verschlusskrankheit (PAVK — 86 Fragebogen). Vasa 1996; 25(1): 32–47

    PubMed  CAS  Google Scholar 

  10. Chetter IC, Spark JI, Dolan P, et al. Quality of life analysis in patients with lower limb ischemia: suggestions for European standardisation. Eur J Vasc Endovasc Surg 1997; 13: 597–604

    Article  PubMed  CAS  Google Scholar 

  11. Hunt SM, McEwen J, McKenna SP, et al. Subjective health of patients with peripheral vascular disease: a randomised clinical trial. Practitioner 1982; 226: 133–6

    PubMed  CAS  Google Scholar 

  12. Brevetti G, Perna S, Sabba C, et al. Effect of Propioryl-L-Carnitine on quality of life in intermittent claudication. Am J Cardiol 1997; 79: 777–80

    Article  PubMed  CAS  Google Scholar 

  13. Cook TA, O’Regan M, Galland RB. Quality of life following percutaneous transluminal angioplasty for claudication. Eur J Vasc Endovasc Surg 1996; 11: 191–4

    Article  PubMed  CAS  Google Scholar 

  14. Dietze S, Kirchberger I, Spengel F, et al. Die Claudicatio-Skala (CLAU-S) ein krankenheitsspezifischer Fragebogen zur Erfassung der Lebensqualität von Patienten mit Claudicatio intermittens, Entwicklung und Validierung. Gefaßchirurgie 1997; 2: 11–7

    Article  Google Scholar 

  15. Boccalon H, Lehert P, Comte S. Claudication intermittante et qualite de vie. Validation des qualites psychometriques de la version francaise du questionnaire CLAU-S. J Mal Vasc 2000; 25(2): 98–107

    PubMed  CAS  Google Scholar 

  16. Spengel FA, Brown TM, Dietze S, et al. The Claudication Scale (CLAU-S): a new disease specific quality of life instrument in intermittent claudication. Dis Manage Health Outcomes 1997; 2 Suppl. 1: 65–70

    Google Scholar 

  17. Liard F, Benichou AC, Gamand S, et al. The effects of naftidrofuryl on quality of life. Dis Manage Health Outcomes 1997; 2 Suppl. 1: 71–8

    Google Scholar 

  18. Romney DM, Evans DR. Toward a general model of health related quality of life. Qual Life Res 1996; 5: 235–41

    Article  PubMed  CAS  Google Scholar 

  19. Wagle G. Multivariate beta distribution and a test of multivariate normality. J R Stat Soc Ser B 1968; 30: 511–6

    Google Scholar 

  20. Ponte E, Cattinelli S. Quality of life in a group of patients with intermittent claudication. Angiology 1996; 47(3): 247–51

    Article  PubMed  CAS  Google Scholar 

  21. Hiatt WR, Nawaz D, Regensteiner J, et al. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil 1988; 12: 525–32

    Article  Google Scholar 

  22. Bollen KA. Structural equations with latent variables. New York (NY): J. Wiley, 1989

    Google Scholar 

  23. Loehlin JC. Latent variable model. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates, 1992

    Google Scholar 

  24. Bentler PM, Stein JA. Structural equation models in medical research. Stat Methods Med Res 1992; 1: 159–81

    Article  PubMed  CAS  Google Scholar 

  25. Andrews FM, Withey SB. Social indicators of well being: Americans’ perception of life quality. New York (NY): Plenum Press, 1976

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Economics, Department of Statistics, University of Mons, Fucam, 151 Chaussee de Binche, 7000, Mons, Belgium

    Philippe Lehert

  2. Faculty of Medicine, Department of Community Health, University of Melbourne, Melbourne, Australia

    Philippe Lehert

Authors
  1. Philippe Lehert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehert, P. Quality-of-Life Assessment in Comparative Therapeutic Trials and Causal Structure Considerations in Peripheral Occlusive Arterial Disease. Pharmacoeconomics 19, 121–130 (2001). https://doi.org/10.2165/00019053-200119020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200119020-00002

Keywords

Search

Navigation